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Summary 
The interleukin 2 receptor (IL-2K) is known to be comprised of at least three genetically distinct 
subunits termed c~, B, and 3/. These chains can be expressed individually or in various combinations 
resulting in distinct receptors with different affinities for IL-2. In contrast to a  and/8, the cell 
surface expression of the 3' chain protein previously has not been well-characterized. To examine 
cell surface expresssion of IL-2R3, on hematopoietic cells, we developed two new monoclonal 
antibodies (mAbs) specific for this protein. Both 1All (immunoglobulin [IgG1]) and 3Gll (IgM) 
specifically reacted with murine cells transfected with IL-2K3" cDNA, and immunoprecipitation 
studies indicated that both antibodies precipitated a protein of approximately 62-65 kD. Scatchard 
analysis of IL-2 binding to murine cells transfected with cDNA-encoding combinations of IL- 
2R components demonstrated that neither B nor 3, chain bind IL-2 with measurable affinity, 
but coexpression of both/8 and 3' is sufficient to form an intermediate affinity receptor. In the 
absence of 3' chain,/8 chain interacts with ot chain to form a "pseudo-high" affinity receptor. 
In contrast, 3' chain does not appear capable of interacting with a  chain in the absence of/8 
chain. Thus, 3' chain appears to interact only with/~, but ~ chain is capable of interacting with 
both  ot  and  3'.  Using  the  newly  developed  mAbs  to  examine  cell  surface expression  by 
immunofluorescence, resting T cells were found to express low levels of 3' chain without detectable 
a  or/8. Early after mitogen stimulation, T cells expressed higher levels of oe,/~, and 3'. However, 
at later time points,  T  cells expressed ot and 3' in marked excess over/8.  Thus, formation of 
high affinity IL-2R on activated T cells was primarily limited by/8 chain expression. In contrast, 
resting natural killer (NK) cells constitutively expressed IL-2RB without detectable cr  or 3'. 
After activation with either IL-2 or IL-12, expression of both c~ and 3' transiently increased and 
then returned to very low levels. Expression of functional IL-2R on resting and activated NK 
cells, therefore, appeared to be primarily limited by the expression of 3' chain. IL-2 binding studies 
with resting NK cells confirmed the results ofimmunofluorescence  studies indicating the presence 
of very low numbers of intermediate affinity (/~3') receptors for IL-2 on these cells.  NK cells 
obtained from patients receiving IL-2 therapy were phenotypically similar to resting NK cells. 
These studies have identified marked differences in IL-2R composition in two different types 
of cytotoxic lymphocytes, further underscoring the complexity of this receptor/ligand system. 
With new reagents specific for IL-2R3", it will now be possible to examine further the functional 
significance of these differences. 
I 
L-2 has pleiotropic effects on lymphocytes, including T, 
B, and NK cells (1-4), as well as other hematopoietic cells 
(5-8). The effects of IL-2 on these various cells are mediated 
through specific cell surface receptors. Over the past several 
years, our understanding of the IL-2R complex has increased 
substantially. It is now known that the IL-2R comprises at 
least three subunits encoded by distinct genes. These subunits 
can be expressed individually or in various combinations, 
resulting in receptors that bind IL-2 with markedly different 
affinity. The first IL-2R component to be identified, IL-2Rc~ 
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with an equilibrium dissociation constant (Ka) of ~10 riM. 
IL-2Rol has a very small intracellular domain and does not 
exhibit homology to other known cytokine receptors.  The 
second IL-2R component, IL-2R3, is a 75-kD protein with 
a large intracellular segment and areas of well-defined ho- 
mology to  other  cytokine receptor  superfamily members 
(10-12).  IL-2R3  is  known  to  play an  important  role  in 
receptor-mediated signaling, in part through association with 
cytoplasmic protein tyrosine kinases (13, 14). The third and 
most recently identified IL-2R component, IL-2R  7, is a 64- 
kD protein that also has structural homology to other cytokine 
receptors (15, 16). Like IL-2R3, IL-2R7 by itself has a very 
low affinity for IL-2 (17). However, when expressed together, 
these two chains form an intermediate affnity receptor with 
a Kd of ",~1 riM. Expression  of all three receptor components 
is required to form a high affinity IL-2 receptor (Kd, "10 
pM). 
Although each component of the IL-2R complex is likely 
to play an important role in regulating the cellular response 
to IL-2, the central role of the 7  chain is supported by the 
demonstration that X-linked SCID occurs as a direct result 
of T  chain mutations (18, 19). In addition, recent studies 
(20-22) have provided compelling evidence that the IL-2R7 
chain is also a component of the receptors  for IL-4 and IL-7. 
Moreover, it is likely that the 3/chain is a common compo- 
nent of additional cytokine receptors.  However, in contrast 
to other IL-2R components, 3/chain mRNA appears to be 
constitutively expressed  in all lymphoid cells. This finding 
is consistent with the demonstration that the IL-2R  7  pro- 
moter sequence is GC-rich and lacks TATA motifs, and sug- 
gests that surface expression of 3' chain is likely to be regu- 
lated primarily by posttranscriptional mechanisms (15, 23). 
However, lack of suitable reagents has previously prevented 
detailed examination of cell surface expression  of IL-2R  7. 
In the present studies we developed two new murine mAbs 
specific for the IL-2R  7  chain. These mAbs have been used 
to examine IL-2R  7  expression by normal human lympho- 
cytes as well as hematopoietic cell lines. To elucidate the func- 
tional consequences of expression of distinct IL-2R subunits, 
the surface expression of each IL-2R component on resting 
and activated T  and NK cells was determined. T  and NK 
cells are known to respond very differently  to IL-2, and these 
studies provide further insight into the mechanisms whereby 
a single cytokine can mediate distinct functional activities in 
different cell types. 
Materials and Methods 
Construction of Plasmids.  A full-length cDNA for human IL- 
2R7 was isolated by RT-PCR using the following oligonucleo- 
tides: 5'-GAAGGCCTTCTGAACACGACAATTCTGACG  (arti- 
ficial StuI  site) or  GCTCTAGAGCGAAGAGCAAGCGCCAT- 
GTTG  (XbaI) and  Y-GCTCTAGAGCCAAATGAAGGGGTG- 
CTTACA (XbaI) from YT cell line mRNA. An expression vector 
containing IL-2R7 cDNA (pMT2.UCHL1 +.IL-2RT.CD45) was 
derived from pMT2.LCA.1 (CD45 O-isoform) (24, 25), and syn- 
thetic oligonucleotides (5'-GCTTCCAAGGATCCGGAAG-3'  and 
5'-CGCTTCCGGATCCTTGGAAGC-3') by ligating appropriate 
restriction  fragments  in  frame. The  resulting  hybrid  protein, 
UCHL1 +.IL-2RT.CD45, contains portions of several proteins in 
the following order: (a) CD45 leader sequence; (b) CD45 amino 
acids 1-8 and 202-218; (c) Ib2R  7 amino acids (L1-N232); (d) seven 
amino acids (RFQGSGS) arising from the synthetic oligonudeo- 
tides; and (e) CD45 amino acids 214-1281 (numbering of CD45 
and IL-2R7 amino acid residues according to Streuli et al. [26] and 
Noguchi et al. [23], respectively). 
The expression vector, pSR~2.IL-2R% was generated by in- 
serting fulMength ID2R7 cDNA into the XbaI multilinker site 
of  a slightly modified  version of the pSRcr  expression vector (27). 
Structures ofplasmid constructs were confirmed  by restriction map- 
ping and/or by nudeotide sequencing. FuU-length  cDNA encoding 
Ib2Rc~ and IL-2RB, were also introduced into the pSRcr  vector 
at  the  appropriate restriction  enzyme  sites, and  designated as 
pSRcc2.1b2Rc~ and pSRc~2.IL-2R~, respectively. 
Transfection ofcDNA.  The Abelson virus-transformed murine 
300-19 pre-B lymphocyte  cell line was transfected  with various  con- 
structs by electroporation with plasmid DNA using the Cell Po- 
rator  Electroporation System (Bethesda Research Laboratories, 
Gaithersburg, MD). pMT2.UCHL1 § .IL-2RT.CD45, pSRc~2.Ib 
2R7, and pSV2.neoSP (28) constructs were linearized  before trans- 
fection with SspI, FspI, and PvuI, respectively. Transfected cells 
were  monitored  using  available anti-CD45  mAbs, UCHL1 
(CD45RO)  and GAP8.3 (CD45). UCHL1  binds to the  NHa- 
terminal region of the 180-kD isoform, whereas GAP8.3 binds to 
a more COOH-terminal region of CD45. In subsequent experi- 
ments, cotransfection  or sequential  transfections  were also performed 
as described above using various combinations of pSRoe2.Ib2Ra, 
pSRoe2.IL-2R3, and pSgoe2.IL-2RT, cr  and/3 chain expression 
vectors were linearized with XmmI. pPGK.Hygro (Hygromycin 
B resistance gene) was used for sequential transfection. 
Production of mAb to the Ib2R T  Chain.  BALB/c  mice were 
immunized  with  300-19(UCHLl§  transfectant 
cells expressing human IL-2R  7 and CD45 epitopes. Fusions were 
carried out as previously described (29), and hybridoma superna- 
tants were screened by indirect immunofluorescence for binding 
to 300-19(UCHL1 +  .IL-2RT.CD45) and lack of binding to 300- 
19(LCA.1) transfectants expressing only human CD45 (25, 30). 
Based on this screening, two hybridomas, designated 1All (IgG1) 
and 3Gll (IgM), were selected and subcloned  by limiting dilution. 
These antibodies also react with 300-19(IL-2RT) cells expressing 
IL-2R7 protein alone (data not shown), confirming that these an- 
tibodies react specifically  with IL-2R7 rather than with CD45RO 
or CD45 epitopes. 
Immunoprecipitation.  The 300-19(Ib2RT) transfectant  cells  were 
surface 125I-labeled by the lactoperoxidase method or were meta- 
bolically labeled with [3SS]methionine (New England Nuclear, 
Cambridge, MA). Radiolabeled  cells were washed and solubilized 
in 1 ml lysis buffer (1% NP-40, 50 mM Tris, pH 8.15, 150 mM 
NaC1, 1 mM EDTA, I mM PMSF, 2/xg/ml PepstatinA, 10/zg/ml 
leupeptin, and 10 #g/ml aprotinin). Lysates  were preincubated  with 
rabbit anti-mouse Ig (RoeM)-coupled protein A beads, followed 
by incubation overnight with specific  antibodies and RoeM-coupled 
protein A beads. Immunoprecipitates were washed extensively, 
followed by addition of sample buffer (60 mM Tris, pH 6.8, 5% 
3-MER, and 2% SDS) and subsequently subjected to SDS-PAGE 
(7.5% gel). 
Cell Lines and lsolation of  Normal Lymphocytes.  T cell lines MT1, 
Jurkat,  Molt4,  H9,  HPB-ALL, and  Rex; B cell lines Daudi, 
SKW6.4, Nalm6, and CESS; NK cell lines NK3.3, YT-N17, and 
YT-2C2; myeloid cell lines K562, HL60,  U937, KG1, TF1, and 
Mo7; colon cancer cell line Colo205; cervical  cancer cell line HeLa; 
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SKMEL were maintained in RPMI 1640 with 10% FBS. NK3.3 
cells (31) were supplemented with 5-10% leukocyte-conditioned 
medium (LCM). TF1 and Mo7 were supplemented with 10 ng/ml 
GM-CSF or 20 ng/ml IIr  The preparation of  LCM was described 
previously (32). 
PBMC  were  isolated  on  Ficoll-diatrizoate  gradients  from 
heparinized blood or from cytophoresis buffy coat cells obtained 
from normal volunteer donors. Adherent mononuclear cells were 
depleted by incubation on plastic petri dishes for 1 h at 37~  En- 
riched NK cells were obtained by incubating PBL with a mixture 
of T1  (CD5),  B1  (CD20),  and  My4  (CD14)  mAb,  and  then 
separating antibody-bound cells using immunomagnetic beads (Ad- 
vanced Magnetics, Inc., Cambridge, MA). In some experiments, 
enriched NK cells cultured in medium with 100 U/ml I1.-2 or PBL 
cultured  in  medium  with  1  /xg/ml  PHA  were  used  for  im- 
munofluorescence experiments.  PBMC  obtained  from patients 
receiving prolonged treatment with low dose rlL-2 (Amgen, Thou- 
sand Oaks, CA) were also examined (33, 34). Chronic administra- 
tion of low dose II.-2 by either continuous i.v. infusion or daily 
subcutaneous injection has previously been shown to expand the 
total number of circulating NK cells and increase cytolytic activity 
against  both NK-sensitive and -resistant  target cells. 
mAbs.  FITC- or PE-conjugated murine mAbs were obtained 
from Coulter Immunology (Hialeah,  FL), including T3 (CD3, 
IgG1), NKH1 (CD56, IgG1), IL-2Pd (CD25, IgG2a), B4 (CD19, 
IgG1), Mo2 (CD14, IgM), and isotype-matched control mAbs. T1 
(CD5,  IgG2a), B1 (CD20,  IgG2a), My4 (CD14, IgG2b), N901 
(CD56, IgG1), 3B8 (CD56, IgM), RW2 (CD3, IgG1), 2ad2 (CD3, 
IgM), UCHL1 (CD45RO), and GAP8.3 (CD45) were used as di- 
lutions of ascites. Purified routine mAbs (FITC conjugated or un- 
conjugated) directed against the p75 subunit (IL-2RB)  (35) were 
kindly provided by Coulter Immunology. Purified 1All (IgG1) and 
3Gli (IgM) antibodies were isolated from ascites by affinity chro- 
matography on an Affi-Gel Protein A MAPS II Kit (Bio-Rad,  Her- 
cules,  CA) or Immunopure IgM Purification Kit (Pierce, Rock- 
ford, IL), and were dialyzed against  PBS. 
Immunofluorescence Analysis.  Samples  of  cells  were  stained 
directly or indirectly with FITC- or PE-conjugated mAb, washed, 
fixed in 1% formaldehyde, and analyzed by flow cytometry as de- 
scribed previously (36). Goat anti-mouse IgM-FITC (Southern Bio- 
technology Associates,  Birmingham, AL) was used as secondary 
antibody for staining of 3Gll  (IgM).  NK3.3  and 1I.-2 activated 
NK ceUs were stained after the incubation in IL-2-free medium 
for 2 h  at 37~ 
RT-PCR and Hybridization.  RT-PCtk and hybridization were 
performed as  described elsewhere  (37,  38).  Primers  specific for 
IL-2K')" were  the  same  as  described above.  Primers  specific for 
/32-microglobulin  were: (nucleotide 1543) 5'-ACCCCCACTGAA- 
AAAGATGA  and (nucleotide 3317) 3'-ATCTTCAAACCTCCA- 
TGATG. 3,-[32p]ATP-labeled  oligomer probes, IL-2R? 5'-TCACAT- 
CCCTCTTATTCCTGC-3', and B2-microglobulin, 5'-GCCCAA- 
GATAGTTAAGTGGG-3', were used for hybridization. 
~2sI-IL2 Binding Assay.  The  12SI-labeled IL-2 was  obtained 
from New England Nuclear or made in one of our laboratories 
(T. L. Ciardelli)  and had a sp act of 1.2-1.5  x  106 or 1.3-1.8  x 
106  dpm/pmol,  respectively.  II.-2 binding  was  analyzed  by 
scatchard plot (39). Briefly, cells (1-3  x  1@ cells per aliquot) were 
incubated at  4~  for  120 min with  125I-IL-2 at  serial  dilutions 
ranging from 1 pM to 64 nM in binding medium containing 1% 
BSA,  0.1%  sodium  azide,  and  25  mM  Hepes  in  RPMI  1640 
medium, pH 7.4, in the presence or absence of a 500-fold excess 
of unlabeled rlL-2. The inhibitory effects of p75 (Ib2R~ antibody), 
and 1All and 3Gll (IL-2R3, antibodies) on 1I.-2  binding were also 
examined in the presence of  excess amount of  antibodies (50/xg/ml). 
Results 
Immunoprecipitation of Antigens  Identified  by Anti-IL-2Rg/ 
mAb.  To confirm the specificity of the newly generated mAb, 
immunoprecipitations were performed using 300-19(IL-2R'y) 
transfectant  ceils.  1All  and  3Gll  precipitate  a  protein  of 
~62-65  kD  from lysates  of cells  surface labeled with  125I 
(Fig.  1 A)  or  metabolically  labeled  with  [35S]methionine 
(Fig.  1 B). Immunoprecipitation of surface-labeled transfec- 
tants  also revealed an intense band  at  ~90  kD  (see Fig.  3 
A).  This  90-kD band  is  also identified in immunoprecipi- 
tates of 125I-labeled YT cells (data not shown).  This protein 
Figure  1.  Immunoprecipitation  of 300-19(IL-2R3,  ) 
cell lysate with 1All and 3Gll mAb. (.4) Cells were 
surface labeled with Na12Sl or (B) metabolically  la- 
beled with [3sS]methionine.  Cell lysates  were precipi- 
tated with either specific  mAb or negative  control  mAb 
and analyzed in 7.5%  SDS-PAGE gel. 
243  Nakarai  et al. A 
~/-8 
o~-5 
~'-8 
13-5 
~-3 
c~-3 
:  ;\  i I, 
'~  ,  ,,,=,,T  ,  ,  ., 
t  t  "  " 
p55(c0 
li  ,  ,  , 
& 
(i 
.i  II  ' 
Lr  i~,  ;~.  .... 
p75(~) 
"  I; 
I  ￿9  !l  ￿9 
}  I  'N...  , 
~i  i  i  " 
,"r  ,'+r 
￿9  t  l=l  . j ',  ., ; 
'il  I 
~'~..~,  !  .r~_..__~.. 
:';  !,, 
:'..  :t 
i' ~,  ~  ,f  ',  ;  .+..~j. x+  ;j. '.,  ._~., 
p64(1A11)  p64(3G11) 
t  ' 
st_ 
IJ.. 
"O 
t,= 
O 
m 
B 
10.0 
7.5 
5.0 
2.5 
10.0  ' 
7.5 
5.0 
2.5 
~--8 
5  10  15 
Kd,  n.d. 
~5 
5  10  15 
Kd,  n.d. 
Bound 
12.5 
10.0 
7.5 
5.0 
2.5 
~-5 
20  40  60  80 
Kd=15.3nM 
Sites/cell=78900 
10.0- 
7.5" 
5.0- 
2.5-~ 
20  40  60 
Kd=13.9nM 
Sites/cell=51000 
15.0  13"~'-3 
o 
10.0 
5.0 
5  10  15 
Kd=1.06nM 
Sites/cell=13700 
Molecules 
25 
0  20  40  60  B0  100 
Kd=0.13nM 
Sites/cell=10200 
Kd=24.8nM 
Sites/cell=96000 
per  Cell  (  x  10-3) 
Figure  2.  (A) Surface expression of IL-2R compo- 
nents in 300-19 transfectant  cell lines. Five 300-19 sub- 
lines designated c~, 3, 3", or3', and/93' were established 
by transfection with various combinations of expres- 
sion vectors. (Dotted lines)  Immunofluorescenee reac- 
tivity with isotype-matched  negative  control  mAb; 
(solid lines) cell surface binding of specific IL-2R anti- 
bodies indicated on the x-axis. (B) Scatchard plot anal- 
yses of t2sI-IL-2 binding on the same transfectant  cell 
lines. Bound Ib2 (molecules/cell)/free  Ib2 (pM) on the 
y-axis are plotted against bound molecules/call on the 
x-axis. 
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further  characterized. 
Expression of lL-2R Components and IL-2 Binding to Trans- 
fectant Cell Lines￿9  Fig. 2 A demonstrates the surface expres- 
sion of the three different human IL-2IL chains on a series 
of murine 300-19 cell lines transfected with cDNA encoding 
individual IL-2R components and a combination of IL-2R 
components. The reactivity of 1All and 3Gll antibodies are 
almost identical, but these antibodies appear to recognize dis- 
tinct epitopes of IL-2R.3( (data not shown). Scatchard plots 
of IL-2 binding to the same transfectants are shown in Fig. 
2 B. Although the IL-2R3( and IL-2R~ transfectants do not 
show detectable IL-2 binding, IL-2RB3( transfectant  cells dem- 
onstrate  intermediate  affinity binding  (Ka,  1.06  riM).  IL- 
2Ro~B transfectant  cells demonstrate both pseudo-high affinity 
binding  (Kd,  0.13  riM)  mediated by the c~/3 complex and 
low affinity binding (Kd, 24.8 riM) mediated by excess free 
c~ chains.  Since the affinity of IL-2 binding to IL-2Ro~ and 
to IL-2Rc~3( transfectant  cells is almost identical (Ko,  15.3 
and 13.9 nM, respectively), expression of the IL-2R3( chain 
does not appear to significantly  affect IL-2 binding to IL-2ILol. 
Expression of lL-2R Chains on YT Cells and Effects of Anti- 
IL-2Ry mAb on IL-2 Binding.  We next examined  surface 
expression of IL-2R3( by immunofluorescence  on cell lines 
known to express high levels of intermediate affinity receptors 
for IL-2. As shown in Fig. 3 A, YT-2C2 cells express both 
IL-2RB and IL-2R3(, but not IL-2Rc~. YT-N17 cells express 
all 3 IL-2R components (data not shown). The fluorescence 
intensity of staining with 3Gll was slightly higher than with 
1All (data not shown). As shown in Fig. 3 B, YT-2C2 cells 
express  a  relatively  high  number  of intermediate  affinity 
receptors for IL-2 (Kd,  1.47 riM,  13,900 sites/cell). The ad- 
dition of excess mAb specific for IL-2RB completely inhibited 
binding of 12SI-labeled IL-2.  In contrast,  IL-2 binding was 
not significantly affected by addition of either mAb specific 
for IL-2R3( (Ka after addition  of 1All  and 3Gll  was 1.81 
and  1.63  nM,  respectively). 
Expression Of  lL-2R'y by Hematopoietic and Nonhematopoietic 
Cell Lines.  Table 1 summarizes  the  surface expression of 
different IL-2R chains detected by flow cytometry and IL- 
2R3( chain message detected by RT-PCR in a large number 
of hematopoietic and nonhematopoietic cell lines.  Although 
most lymphoid cell lines revealed levels of IL-2R3( chain ex- 
pression detectable both by immunofluorescence  and  RT- 
PCR,  surface expression of IL-2R3( chain was generally at 
relatively low levels. Of all cell lines tested,  surface expres- 
sion of IL-2R3( was highest in the YT cell lines.  Four non- 
hematopoietic cell lines were not found to express IL-2R3( 
by either immunofluorescence  or RT-PCR. 
Expression of IL-2R3( by myeloid cell lines has not been 
previously reported￿9 Although all six myeloid cell lines that 
we tested expressed IL-2R3( mRNA by RT-PCR, relatively 
low surface expression of y chain was detected by flow cytom- 
etrv in  two cell lines  (Table  1). 
Expression of IL-2R  Components after Activation of T and 
NK Cells.  We also examined changes in surface expression 
of the three IL-2R components on PHA-activated T  cells 
(CD3 + cells) and IL-2-activated NK cells (CD56 + cells). As 
shown in Fig. 4, almost no ~  or B chain was detectable by 
flow cytometry on resting T  cells, but 3' chain was present 
at low levels. After PHA stimulation (48 h), surface expres- 
sion of ol chain increased markedly while ~  and 3( chain ex- 
pression increased to a smaller extent. By 5 d after activation, 
both ~  and/3  chain expression had declined.  Although 
chain expression remained increased compared with resting 
T cells,/3 chain expression had almost returned to very low 
baseline levels.  In contrast,  3( chain expression appeared to 
be increased compared with resting T cells and exceeded that 
of/3 chain. 
Fig. 5 A  shows the surface expression of the three IL-2R 
components on enriched NK cells after IL-2 activation.  As 
previously shown,/~  chain was constitutively expressed by 
resting NK cells. Both CD56 ~m and CD56b'ig ht NK popu- 
lations expressed IL-2R/3, but neither population expressed 
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Figure 3.  (.4)  Immunofluorescence  reactivity of anti-p64 mAb with YT cell line. YT cells were stained directly with anti-p55-FlTC (lgG1) and 
anti-p75-FITC (IgG2a) or indirectly with 1All and 3Gll. Immunofluorescence  reactivity was compared with negative controls. (Dotted  lines) MslgG1- 
FITC, MslgG2a-FITC, MslgG, and MslgM. (B) Scatchard  plot analyses of 12sI-IL-2  binding to YT cells. Binding studies were carried out in the pres- 
ence of media (e) or excess  mAb 1All (A), 3Gll ([3), and anti-p75 (<>). Bound IL-2 (molecules/cell)/free  Ib2 (pM) on the y-axis are plotted against 
bound molecules/cell on the x-axis. 
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IL-2Rt~ 
p55 
Surface immunofluorescence 
IL-2RB 
p75 
IL-R3, 
p64 
RT-PCR 
IL-R3' 
p64 
T  cell lines 
MT1 
Jurkat 
Molt4 
H9 
HPB-ALL 
REX 
B cell lines 
Daudi 
SKW6.4 
Nalm6 
CESS 
NK cell lines 
YT N17 
YT 2C2 
NK3.3 
Myeloid cell lines 
K562 
HL60 
U937 
KG1 
TF1 
Mo7 
Nonhematopoietic  cell lines 
Colo205 
HeLa 
SW2 
SKMEL 
++ 
m 
++ 
++ 
++ 
++ 
++ 
m 
m 
++ 
++ 
+ 
Cells were stained directly  with p55-FITC or p75-FITC, or indirectly  with 3Gll ascites and goat anti-mouse IgM-FITC. Fluorescence  intensity  for 
each antibody  was compared  with isotype-matched  negative control antibody. (-) <5% reactivity  above negative control fluorescence;  (+) 5-30% 
reactivity; (+ +) >30% reactivity. 
detectable ot or 3' chain. 5 d after activation, NK cells demon- 
strated enhanced expression of both c~ and 3' chain.  How- 
ever, expression of both ot and 3" chain remained at a lower 
level compared with IL-2RB. By 15 d after stimulation, ex- 
pression of  both ot and 3' chains had decreased to the baseline 
level of resting NK cells but/3 chain expression remained 
stable. Analysis of NK cells after activation with IL-12 gave 
similar results (data not shown). Thus, NK cells also demon- 
strated a discordance between expression of the/3 and 3" chains 
but, in contrast to T cells, expression of/3 chain was always 
in excess and surface expression of 3" chain appeared to repre- 
sent the limiting component. 
We also  examined the expression of IL-2R components 
on PBMC obtained from patients receiving prolonged con- 
tinuous infusions of low dose IL-2.  Previous studies have 
demonstrated that such therapy results in the gradual expan- 
sion of circulating CD56 § CD3-  NK cells, which become 
the predominant lymphocytes in peripheral blood after 4-6 
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Figure 4.  Surface  expression  of IL-2R subunits on resting and mitogen- 
stimulated T (CD3 +) cells. T cells were examined after 2 and 5 d of cul- 
ture with 1 #g/ml PHA. Ib2R3~ expression was determined by staining 
cells indirectly with 1All/anti-mouse  IgG1-FITC or 3G11/anti-mouse 
IgM-FITC followed by CD3-PE.  Ib2Kol  and IL-2RB were examined 
directly  with anti-p55-FITC  and anti-P75-FITC  in combination  with CD3- 
PE. Quadrant settings distinguishing positive immunofluorescence  from 
background fluorescence  were determined  by staining with isotype-matched 
control mAb (not shown). 
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wk of treatment  (33, 34).  As shown in Fig.  5 B, in vivo- 
expanded NK cells in such patients express IL-2R~ but little 
IL-2Rc~ and  IL-2R%  The pattern of expression of IL-2R 
components in in vivo expanded NK cells is thus similar to 
that  seen in normal resting  NK cells. 
IL-2 Binding to Resting NK Cells.  To confirm the low level 
of expression of y  chain on resting NK cells, we conducted 
three  independent  IL-2  binding  experiments  on  enriched 
resting NK cells to determine the number of intermediate 
affinity IL-2 binding sites (Table 2). The percentage of NK 
cells  (CD56 +)  in  these  experiments  was  between  56  and 
64%. Further analysis of these populations indicated that they 
contained 15-26% CD3 § cells and '~20% other cells which 
were not identified. Scatchard analysis of IL-2 binding sites 
revealed the presence of both high and intermediate affinity 
IL-2 receptors. However, calculation of the number of IL-2 
binding  sites in these populations  revealed only ",~180-280 
intermediate  affinity binding  sites  and  10-35  high  affinity 
binding sites per cell. These findings are consistent with very 
low levels of expression of both IL-2Rot and IL-2R%  de- 
spite relatively high expression of IL-2RB.  Assuming  that 
contaminating cells in this analysis have no IL-2 binding capa- 
O 
14. 
￿9  1  100e 
o 
LO 
r,-  fl. 
.1  leee 
.1  leee 
CD56-PE 
Figure 5.  (A) Surface  expression 
of IL-2R subunits on Ib2-activated 
enriched  NK  cells and  (B)  in 
vivo-expanded NK cells from pa- 
tients receiving prolonged Ib2 in- 
fusion. Enriched NK cells were ex- 
amined after 5 and 15 d of culture 
with 100 U/ml Ib2. NK calls from 
patients receiving Ib2 were exam- 
ined without in vitro cuhure. Ib 
2R',/expression was determined  by 
staining  cells indirectly  with 
1All/anti-mouse  IgG1-FITC or 
3G11/anti-mouse IgM-FITC  fol- 
lowed by CD56-PE. lI:2Rc~ and IL- 
2Pq8 were examined directly with 
anti-p55-FITC and anti-P75-FITC 
in  combination with  CD56-PE. 
Quadrant  settings distinguishing 
positive immunoftuorescence  from 
background fluorescence  were de- 
termined by staining with isotype- 
matched control mAb (not shown). 
247  Nakarai  et al. bility, the true number of IL-2 binding sites on resting NK 
cells may increase from one- to twofold. Nevertheless, these 
results remain  consistent with  our flow cytometric results 
indicating very low levels of expression of both ot and 3, chain 
in resting  NK cells. 
Discussion 
The IL-2R is a complex receptor that includes at least three 
distinct  subunits.  Depending  on  the  expression  of these 
subunits, cells can possess receptors with markedly different 
affinities  for IL-2 as well as different functional  attributes. 
The B and 3, chains are members of a large cytokine receptor 
family characterized by four conserved cysteine residues and 
a Trp-Ser-X-Trp-Ser  (WSXWS) motif in two fibronectin type 
III modules. Both IL-2RB and IL-2R3, possess large cyto- 
plasmic domains that presumably contribute to signal trans- 
duction upon IL-2 binding (13, 14, 18, 40). In contrast, IL- 
2Rol has a very small cytoplasmic segment and has not been 
shown to mediate IL-2 internalization or signal transduction 
by  itself.  Nevertheless,  IL-2Rct  appears  to  facilitate  IL-2 
delivery to other IL-2R subunits and promotes the forma- 
tion  of high  affinity receptors (41). 
Previous studies have demonstrated that the gene encoding 
the IL-2R3, chain appears to be constitutively transcribed by 
a variety of lymphoid and myeloid cells. This is compatible 
with data indicating that the 3, chain gene does not include 
c/s-acting elements typically associated with inducible expres- 
sion. Thus, surface expression of the 3, chain is probably regu- 
lated posttranscriptionally.  However, studies of 3, chain pro- 
tein expression have heretofore been impeded by a lack of 
suitable reagents. In the present studies we describe two new 
Table  2.  Immunofluorescence Analysis  and 12sI-IL-2 
Binding to Enriched Resting NK  Cells 
12sI-IL2 binding 
CD56  CD3  CD19  CD14  Ka  Sites/cell 
%  eM 
1.  62.7  15.9  ND  0.42  5.1  10 
236  277 
2.  64.2  16.8  ND  0.97  6.9  27 
349  281 
3.  56.4  26.1  0.1  4.2  3.2  34 
308  187 
Enriched resting NK cells obtained after immunomagnetic bead deple- 
tion of T cells, B cells, and monocytes  were stained directly  with CD56-PE, 
CD3-FITC, CD19-FITC, CD14-PE, and isotype-matched control anti- 
bodies. Gates were set to include all mononuclear cells and percent posi- 
tive cells represent percent total mononuclear cells. IL-2 binding assay 
was performed as described  in Materials and Methods. ND, not detected. 
murine mAbs,  1All  and 3Gll,  specific for the human  IL- 
2R3, subunit, and have used these new reagents to examine 
expression of the 3' chain in a variety of cell lines transfected 
with different IL-2R components as well as a large number 
of other hematopoietic cells. 
Examination  of surface expression of IL-2R components 
in a murine pre-B cell line transfected with different combi- 
nations  of human cDNA encoding IL-2Rot,  IL-2R~,  and 
IL-2R3, confirmed the specificity of the new mAbs. Immune 
precipitation  studies also confirmed the reactivity of these 
mAbs with  a cell surface protein  with  molecular mass of 
",~62-65 kD. It is interesting to note that further analysis of 
IL-2 binding to these transfectant cell lines demonstrated that 
neither/8 nor 3, chain bind IL-2 with measurable affinity and 
that  coexpression of these two chains is sufficient to form 
an intermediate affinity receptor. In the absence of 3, chain, 
/8 chain clearly interacts with ot chain to form a pseudo-high 
affinity receptor. In contrast, 3, chain does not appear capable 
of interacting with ot chain in the absence of/3 chain. In the 
formation of various IL-2R, these results indicate the 3, chain 
only interacts with/8, but that/3 chain interacts with both 
ot and 3,. 
Despite the ubiquitous presence of 3, chain message in the 
hematopoietic cells we examined,  cell surface 3, chain was 
detected primarily on lymphoid cells. We undertook detailed 
studies of IL-2R subunit expression on T  and NK cells be- 
cause these lymphocytes exhibit distinct functional responses 
to IL-2. Resting T lymphocytes were found to express very 
low levels of IL-2R3, chain,  whereas both ot and/3 chains 
were essentially undetectable. After stimulation with PHA, 
virtually all T cells expressed IL-2Rot at high levels; IL-2R/8 
and 3, were more modestly upregulated.  Thus,  activated T 
cells appear to express a small number of heterotrimeric high 
affinity IL-2R that  are limited by the number of/8 and 3, 
chains on the cell surface.  The expression of an excess of ot 
chain  appears  to  promote  the  formation  of high  affinity 
receptors capable of responding to very low concentrations 
of IL-2. Subsequently, ~  chain expression returns  to unde- 
tectable levels and the number of or chains also declines, whereas 
3, chain expression remains elevated.  Since ot and 3, do not 
appear to interact with  each other,  the downregulation  of 
expression appears to be an important mechanism for lim- 
iting the T  cell response to IL-2 in the absence of further 
stimulation. In this setting, it seems likely that 3, chains that 
persist after T cell activation are associated with other cytokine 
receptors, such as IL-4R and IL-7R. In fact, the selective down- 
regulation of B chain may directly promote the interaction 
of the 3, chain with other cytokine receptors, thus providing 
a mechanism for directing a sequential response to different 
cytokines. Similarly,  the selective low level expression of 3, 
chain without either o~ or B on resting T cells may indicate 
that 3, chain is complexed with receptors for other cytokines 
before T  cell activation. 
Resting NK cells incubated with  nanomolar  concentra- 
tions of IL-2 exhibit augmented cytolytic activity and up- 
regulation of cell surface adhesion molecules (4). These data 
imply that NK cells constitutively express intermediate affinity 
248  Ib2R 3' Chain Expression on Resting and Activated Lymphoid Cells IL-2R, and it has been established that virtually all resting 
NK cells express IL-2R/3 (39, 42), Although the/3 chain was 
dearly detected on resting NK cells, our immunofluorescence 
studies revealed almost no surface staining for the 3" chain. 
Furthermore, our radiolabeled IL-2 binding studies detected 
only 'o300 intermediate affinity IL-2R on resting NK cells, 
which is compatible with the immunofluorescence data.  In 
this regard, normal NK cells resemble the expanded NK cell 
population in the peripheral blood of cancer patients receiving 
low dose IL-2 therapy.  We found that  such expanded NK 
cells also express IL-2R/3 in excess of IL-2ot and IL-2Ry by 
immunofluorescence analysis. Voss et al. (43) have previously 
shown that NK cells expanded in vivo after high dose IL-2 
express abundant  IL-2R/3, but only a small fraction of the 
/3 chains appear to be associated with 3' chains.  Although 
Nagler et al. (42) have reported that NK cells express a rela- 
tively high number of intermediate affinity binding sites per 
cell,  our results are more consistent with those of Voss et 
al.  (43),  indicating  only a relatively low number  of inter- 
mediate  affinity IL-2R on resting  NK cells. 
After in vitro activation, expression of the/3 chain on NK 
cells remains relatively unchanged whereas both IL-2Rot and 
IL-2R3" are upregulated.  Thus,  activated NK cells express 
a relatively low number of high affinity heterotrimers  and 
intermediate affinity/33' heterodimers together with an excess 
of presumably nonfunctional/3 chains. With more prolonged 
culture,  ot and 3, chain expression declines to background levels, 
leaving only/3 chain detectable on the cell surface.  In con- 
trast to T  cells, we did not find persistent y  chain on long- 
term activated NK cells. The very low expression of 3" chain 
on either resting or activated NK cells also suggests that these 
cells would not be responsive to other cytokines that use the 
3' chain  to facilitate cell surface interactions. 
The differences in IL-2R subunit expression by T and NK 
cells underscore the distinct  role of IL-2 in the biology of 
these lymphocytes. Naive, resting T cells do not express func- 
tional IL-2R.  After stimulation  with antigen  or mitogen, 
T  cells  secrete IL-2 and express high  affinity IL-2R heter- 
otrimers. Furthermore,  autocrine stimulation via the IL-2/ 
IL-2R  pathway  supports  the  proliferation  and  functional 
differentiation of effector T cells. Upon withdrawal or clear- 
ance of antigen,  T  cells downregulate both IL-2Rc~ and/3 
but appear to become unresponsive to exogenous IL-2 pri- 
marily because of the marked decrease in expression of/3 chain. 
In contrast to T  cells, resting NK cells express intermediate 
affinity IL-2R and can respond to IL-2 in the absence of other 
stimuli.  We have demonstrated that  resting NK cells con- 
stitutively express a very small number of functional/33" het- 
erodimers and a large excess of isolated/3 chains.  The iso- 
lated/3  chains  would only bind IL-2 with  extremely low 
affinity and may not be functional under physiologic condi- 
tions.  Thus  the IL-2 response of resting  NK ceils  appears 
to be regulated primarily by the limited expression of both 
oe and 3' chain. 
Despite constitutive expression of 3' chain message by lym- 
phoid cells, we have demonstrated that 3' chain protein ex- 
pression is tightly and differentially regulated on distinct lym- 
phocyte subsets. It is likely that the precise composition of 
the IL-2R and of other multi-chain  receptors that  include 
the 3' chain will be different on various other hematopoietic 
cells. In conjunction with mAbs specific for other IL-2R com- 
ponents, mAbs specific for IL-2R3" should be useful reagents 
to elucidate the biology of complex hematopoietic cytokine 
receptors. 
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